Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70

Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol (2015) 1.65

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37

Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer (2012) 1.26

IL-6 gene amplification and expression in human glioblastomas. Br J Cancer (2001) 1.14

The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13

STAT signaling in the pathogenesis and treatment of cancer. Mol Med (1999) 1.11

IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol (2011) 1.07

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant (2005) 1.00

Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clin Exp Metastasis (2004) 0.98

IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer (2001) 0.97

Natriuretic peptide receptor a as a novel target for prostate cancer. Mol Cancer (2011) 0.91

Proinflammatory cytokine interleukin-6 in prostate carcinogenesis. Am J Clin Exp Urol (2014) 0.87

Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma. BMC Cancer (2013) 0.87

Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem (2012) 0.87

STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance. Front Oncol (2015) 0.86

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer (2015) 0.85

SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growth. Oncotarget (2016) 0.83

Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One (2011) 0.83

Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br J Cancer (2007) 0.83

Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med (1999) 0.81

Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Br J Cancer (2000) 0.80

Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS One (2009) 0.80

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer (2015) 0.79

The role of interleukin-6 in malignant mesothelioma. Transl Lung Cancer Res (2015) 0.78

Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway. Oncotarget (2016) 0.75

IL-6 Inhibition Reduces STAT3 Activation and Enhances the Antitumor Effect of Carboplatin. Mediators Inflamm (2016) 0.75

Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression. Sci Rep (2017) 0.75

Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene (2006) 4.06

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46

An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients. Cancer (1996) 3.12

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38

Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol (1996) 2.25

Transfusion-associated graft-versus-host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second-degree relative, and a survey of predisposing factors. Transfusion (1993) 2.22

Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol (2000) 2.13

Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol (2000) 2.06

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J (2001) 1.82

Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol (1979) 1.80

Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res (2001) 1.59

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 1.59

Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54

Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.53

Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. Cancer J (2001) 1.46

Human tear lysozyme. II. Quantitative determination with standard Schirmer strips. Am J Ophthalmol (1968) 1.46

Evidence for several cell populations active in antibody dependent cellular cytotoxicity. J Immunol (1973) 1.44

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol (1992) 1.43

Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. J Immunol (1982) 1.42

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40

Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol (1992) 1.39

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol (1999) 1.36

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. J Immunol (1986) 1.34

Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. J Immunol (1974) 1.34

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene (2009) 1.34

Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther (2001) 1.33

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33

The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. J Exp Med (1988) 1.30

Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol (1996) 1.30

Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol (1979) 1.29

Selective lysis of NK-sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes. J Immunol (1981) 1.26

Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem (1989) 1.25

Studies on the induction and expression of T cell-mediated immunity. X. Inhibition by Lyt 2,3 antisera of cytotoxic T lymphocyte-mediated antigen-specific and -nonspecific cytotoxicity: evidence for the blocking of the binding between T lymphocytes and target cells and not the post-binding cytolytic steps. J Immunol (1980) 1.25

Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol (1999) 1.24

Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer (2002) 1.22

Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol (1980) 1.21

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am (1997) 1.18

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol (1997) 1.16

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus (2000) 1.16

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol (1987) 1.15

Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. J Urol (2000) 1.15

Histamine-receptor leucocytes (HRL). Organ and lymphoid subpopulation distribution in man. Clin Exp Immunol (1977) 1.13

Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents (2003) 1.13

Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells. J Immunol (1983) 1.13

Concanavalin A-mediated activation of antigen-primed lymphocytes into secondary cytotoxic lymphocytes. J Exp Med (1977) 1.13

Histamine receptor-bearing leukocytes (HRL). I. Detection of histamine receptor-bearing cells by rosette formation with histamine-coated erythrocytes. J Immunol (1974) 1.13

Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. J Immunol (1990) 1.13

Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol (1997) 1.11

Incidental renal tumors. Urology (2000) 1.11

Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol (1995) 1.11

Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol (1999) 1.10

Gene and immune-based therapies for genitourinary malignancies: current status and future prospects. Isr Med Assoc J (2000) 1.07

Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells. J Clin Immunol (1988) 1.07

Lectin-dependent cellular cytotoxicity in man. Transplantation (1977) 1.06

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med (1987) 1.05

Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol (1995) 1.04

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene (2007) 1.04

Antibody dependent cellular cytotoxicity: cytotoxicity mediated by non t-lymphocytes. Clin Immunol Immunopathol (1974) 1.03

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol (2001) 1.03

Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol (1991) 1.03

Specific antibodies to dinucleotides and trinucleotides. Eur J Biochem (1972) 1.02

Renal cell carcinoma: recent progress and future directions. Cancer Res (1997) 1.02

Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay. J Immunol (1982) 1.02

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene (2006) 1.02

Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun (1999) 1.02

Positron emission tomography in urological oncology. J Urol (1998) 1.02

The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother (1997) 1.01

Proteins in human tears. I. Immunoelectrophoretic patterns. Arch Ophthalmol (1969) 0.99

Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens. Cancer Res (1976) 0.99

Incidentally discovered mass of the adrenal gland. Surg Gynecol Obstet (1986) 0.99

Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). J Immunol (1987) 0.98

2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clin Immunol (2008) 0.98

Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. J Urol (1989) 0.98

Extrarenal angiomyolipomas of the perinephric space. J Urol (1992) 0.97

Prolonged asymptomatic states in HIV-seropositive persons with 50 CD4+ T-cells/mm3: preliminary psychoimmunologic findings. J Acquir Immune Defic Syndr (1993) 0.97

Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol (1996) 0.97

Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer (1999) 0.97

Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates. Cancer Res (1998) 0.96

Mechanism of cell-mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. J Immunol (1984) 0.96

Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer (1994) 0.96

Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia (2008) 0.96

Human tear lysozyme. 3. Preliminary study on lysozyme levels in subjects with smog eye irritation. Am J Ophthalmol (1968) 0.96

Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res (1993) 0.95

Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol (1999) 0.95

Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell Immunol (1982) 0.95

Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. Proc Natl Acad Sci U S A (1990) 0.94

Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. Int J Oncol (1998) 0.94

The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth. Adv Cancer Res (1983) 0.93

Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res (1995) 0.93

CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol (2000) 0.93

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res (2001) 0.92

Autoimmunity and aging: the age-related response of mice of a long-lived strain to trinitrophenylated syngeneic mouse red blood cells. J Immunol (1976) 0.92

Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res (1999) 0.92

Immunological unresponsiveness induced in adult mice to synthetic polypeptides built on multichain polyproline and multichain polyalanine. Immunochemistry (1974) 0.92

Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol (1993) 0.92

Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res (1997) 0.92

Frequency determination of killer cells by a single-cell cytotoxic assay. Methods Enzymol (1983) 0.92

Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. J Clin Immunol (1996) 0.92